Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
150 Leser
Artikel bewerten:
(0)

Global Biochip Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are Abbott, Agilent Technologies, Illumina, PerkinElmer & Thermo Fisher Scientific

DUBLIN, September 5, 2017 /PRNewswire/ --

The "Global Biochip Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global biochip market is forecast to grow at a CAGR of 17.53% during the period 2017-2021.

The report, Global Biochip Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is growth in bioinformatics software industry. Bioinformatics software is a tool that is used in data collection, mining, database construction, and analysis of data. This tool is used in to create analysis results out of the massive amount of data that had been already collected. Along with this, bioinformatics software is also used in the field of genomics and proteomics. It helps in the identification and analysis of abnormalities in the genome of an organism.

According to the report, one driver in the market is increase in market presence with collaboration strategy. The competition in this market is intense as the number of players is high. The players are competing among themselves based on technology and price. Apart from these two factors, another factor that differentiates these competitors from each other is their presence in the market. Players increase their market presence by collaborating with those companies that own bio-content. Research says that companies generate around 60% better results when they work in collaborations. This increases their profit margins. They collaborate with each other for R&D, financial resources, and intellectual properties.

Key vendors

  • Abbott
  • Agilent Technologies
  • Illumina
  • PerkinElmer
  • Thermo Fisher Scientific

Other prominent vendors

  • BioChain
  • Bio-Rad Laboratories
  • Cepheid
  • EMD Millipore
  • Fluidigm
  • SuperBioChips Laboratories
  • US Biomax

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market segmentation by fabrication technology

PART 06: Geographical segmentation

PART 07: Decision framework

PART 08: Drivers and challenges

PART 09: Market trends

PART 10: Vendor landscape

PART 11: Key vendor analysis

PART 12: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/rqlbg6/global_biochip

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.